THC’s competitive advantage is its ability to produce high quality pharmaceutical GMP medicinal cannabis at a low cost. The company has developed proprietary cannabis strains THC Global Group Ltd ( ASX:THC ) is making progress towards launching Australian medicinal cannabis products for Australian patients in early 2020 and become the first company to do this at commercial scale. The company will be targeting to have medicinal cannabis available to the 100,000+ patients expected in the near term within Australia as well as being a global exporter. Farm to pharma vertical integration THC’s competitive advantage is its ability to produce high quality pharmaceutical GMP medicinal cannabis at a low cost – owing to its proprietary cannabis strain IP and its world-class manufacturing facility. THC’s Australian cannabis facilities This competitive advantage will enable THC to supply medicinal cannabis to Australian patients at a significantly lower cost than the current cost of […]